Abpro Holdings, Inc. (ABP)
| Market Cap | 42.29M |
| Revenue (ttm) | 230,000 |
| Net Income (ttm) | -7.72M |
| Shares Out | 50.52M |
| EPS (ttm) | -0.82 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 101,672 |
| Open | 0.975 |
| Previous Close | 0.951 |
| Day's Range | 0.800 - 0.999 |
| 52-Week Range | 0.800 - 13.000 |
| Beta | -0.39 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Mar 7, 2025 |
About ABP
Abpro Holdings, Inc., a biotechnology company, provides antibody therapeutics for cancer related issues. Its platform DiversImmune addresses the antibody therapeutics. The company’s product candidates include ABP-102 for the treatment of breast and gastric cancer; and ABP-110 for the treatment of liver cancer. It also offers ABP-105 for the treatment of gastric cancer and ABP 201 for vascular diseases of the eye and diabetic macular edema. Abpro Holdings, Inc. was incorporated in 2004 and is based in Woburn, Massachusetts. [Read more]
Financial Performance
In 2023, Abpro Holdings's revenue was $122,000, a decrease of -93.99% compared to the previous year's $2.03 million. Losses were -$11.71 million, -32.00% less than in 2022.
Financial StatementsNews
Abpro Holdings Celebrates Closing of Business Combination with Nasdaq Bell Ringing
WOBURN, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq:ABP) (“Abpro”), a biotech company with the mission of improving the lives of mankind facing severe and life-threatening di...